Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.480
0.00 (0.00%)
At close: Aug 28, 2025, 4:00 PM
1.420
-0.060 (-4.05%)
After-hours: Aug 28, 2025, 4:18 PM EDT
Telomir Pharmaceuticals Employees
As of December 31, 2023, Telomir Pharmaceuticals had 9 total employees, including 1 full-time and 8 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,786,536
Market Cap
47.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TELO News
- 8 hours ago - Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases - Accesswire
- 21 days ago - Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction - Accesswire
- 5 weeks ago - Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's - Accesswire
- 5 weeks ago - Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Accesswire
- 2 months ago - Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging - Accesswire
- 2 months ago - Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - Accesswire
- 3 months ago - Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Accesswire
- 3 months ago - Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Accesswire